Why do peptides degrade so quickly in the body?

The body contains a large number of proteases and peptidases — enzymes specifically designed to cleave peptide bonds. These are found in plasma, the gastrointestinal tract, and tissue membranes. Most endogenous peptides are designed to act rapidly and then clear quickly, so the biological machinery for breaking them down is efficient and widespread. Unmodified, native peptide sequences are often degraded within minutes of entering biological fluids.

What is the difference between enzymatic and chemical peptide degradation?

Enzymatic degradation involves proteases recognising and cleaving specific sequences in a peptide chain — it's biologically driven and the dominant pathway in vivo. Chemical degradation, by contrast, occurs independently of enzymes; it includes hydrolysis driven by pH and temperature, and oxidation of vulnerable amino acid side chains (such as methionine or cysteine) triggered by oxygen, light, or metal ions. Both pathways reduce a peptide's biological activity, but they operate through different mechanisms and are managed differently in formulation and storage.

How does lyophilisation (freeze-drying) help preserve peptides?

Lyophilisation removes water from a peptide sample, which dramatically slows the hydrolysis reactions responsible for peptide bond cleavage and the oxidative reactions that degrade sensitive residues. In the dry, lyophilised state, stored at appropriate temperature, peptides are generally far more stable than in aqueous solution. Once a peptide is reconstituted in a liquid vehicle, the stability window shortens considerably — which is why reconstituted solutions are typically used promptly or stored under refrigeration.

What structural modifications can improve peptide stability?

Researchers have developed several strategies: substituting D-amino acids (mirror-image forms) at susceptible sites blocks recognition by stereospecific proteases; N-methylation of backbone amide nitrogens disrupts protease binding; cyclisation through disulfide bridges or lactam bonds constrains the molecule and reduces enzymatic access; and PEGylation — attaching polyethylene glycol chains — can sterically shield cleavage sites while also reducing renal clearance. Each modification changes the pharmacokinetic profile, often substantially.

Are peptides legally available in Australia?

Some peptide-based medicines are legally available in Australia when prescribed under the appropriate regulatory framework — either as registered therapeutic goods on the ARTG, or accessed by a prescriber through the TGA's Special Access Scheme or the Authorised Prescriber pathway. However, many peptides marketed online, particularly for performance or anti-ageing purposes, are not TGA-approved. Supplying unapproved therapeutic goods in Australia is illegal under the Therapeutic Goods Act 1989, and the TGA has actively enforced compliance in this area.

Peptide Stability and Degradation

By Priya Nandakumar · 2 July 2026 · 7 min read

The molecule that can't hold itself together

Roughly 7,000 naturally occurring peptides have been identified in the human body. Most of them have a half-life measurable in minutes. That fact alone should tell you something important about how these molecules behave once they leave the controlled environment of a living cell , or, for that matter, a well-run cold chain.

I've been thinking about this a lot lately after revisiting some older pharmacokinetics data from a study I keep returning to. The numbers on plasma half-lives for unmodified peptides are genuinely humbling. A peptide that looks perfectly stable on paper can become undetectable in biological fluid within fifteen minutes. Understanding why that happens is the whole game, whether you're reading about research molecules or trying to make sense of how any peptide-based medicine gets from the lab to a usable form.

So let's start at the bond itself.

What a peptide bond actually is , and why it's the weak link

A peptide bond is the covalent linkage between the carboxyl group of one amino acid and the amino group of the next. It's what strings a chain of amino acids into a peptide in the first place. Textbooks describe it as relatively stable under normal physiological conditions, which is true , but "relatively" is doing a lot of work in that sentence.

The bond is susceptible to hydrolysis. Water, in the presence of the right catalyst, can cleave it. In biological systems, that catalyst is almost always an enzyme: a protease or peptidase, and the body has dozens of them circulating in plasma, lining the gastrointestinal tract, and embedded in the membranes of various tissues. Aminopeptidases attack from the N-terminus. Carboxypeptidases work from the C-terminus. Endopeptidases go after internal sequences. The body is, from a peptide's perspective, a very hostile place.

This isn't a flaw in our biology. It's the system working exactly as designed. Regulatory peptides; hormones, neuropeptides, signalling molecules, are meant to act fast and clear fast. A world where endogenous peptide signals lingered for hours would be pharmacologically chaotic. But it does create a real challenge for anyone trying to use a peptide as a research or therapeutic tool.

The four main degradation routes

Enzymatic cleavage is the most obvious mechanism, but it's not the only one. There are four major degradation pathways worth understanding.

Enzymatic proteolysis is, as described above, the dominant route in vivo. The gastrointestinal tract is particularly aggressive, which is a large part of why oral bioavailability for unmodified peptides is almost always poor. First-pass metabolism further reduces what reaches systemic circulation for anything that does manage to cross the gut wall.

Chemical hydrolysis occurs independently of enzymes, driven purely by pH and temperature. Aspartyl residues are especially vulnerable; they're prone to forming cyclic imide intermediates that open into isoaspartyl forms, which changes the molecule's shape and can knock out biological activity entirely.

Oxidation is a particular risk for peptides containing methionine, cysteine, or tryptophan residues. Exposure to dissolved oxygen, metal ions, or UV light can oxidise these side chains. Storage conditions matter enormously here. A peptide solution left in ambient light at room temperature is essentially a slow oxidation experiment.

Aggregation is the degradation pathway people talk about least, but it's probably the one that causes the most headaches in formulation science. Under certain conditions; wrong pH, freeze-thaw stress, agitation, peptides misfold and stick to each other. Once you have aggregates, you've lost activity and potentially introduced immunogenicity risk.

Why storage conditions are not a minor detail

Honestly, I think the gap between how carefully researchers think about peptide chemistry and how casually people sometimes discuss storage is one of the bigger disconnects in this space. And it matters in a direct, practical way.

Temperature is the first variable. Most research-grade peptides are lyophilised (freeze-dried) for long-term storage, because removing water dramatically slows hydrolysis and oxidation. Once reconstituted in solution, the clock is running. At 4°C, many peptide solutions retain useful stability for days to weeks. At room temperature, that window collapses. At -20°C in the dry, lyophilised state, properly formulated peptides can remain stable for considerably longer, though not indefinitely, and not if the freeze-thaw cycle is handled sloppily.

pH is the second major variable. Most peptides have an optimal pH range; often mildly acidic, where hydrolysis is slowest. Drift too far in either direction and degradation accelerates. Phosphate-buffered saline at physiological pH (7.4) is convenient for biological work but is not always the most stable storage vehicle for a given peptide.

The third variable is often overlooked: the container. Peptides adsorb to certain surfaces, particularly glass and some plastics, which means a portion of your molecule never makes it into solution at all. Low-binding plasticware is standard practice in careful peptide work for exactly this reason.

Structural modifications that change the stability picture

A lot of the research interest in modified peptides comes down to this stability problem. Native sequences degrade too fast to be practically useful in many contexts, so chemists have developed a toolkit of modifications designed to slow the process down.

N-methylation of the backbone amide nitrogen removes the hydrogen bond donor that enzymes often use for recognition, making the bond harder to cleave. D-amino acid substitutions, swapping in the mirror-image form of an amino acid; can block enzymatic attack because most proteases are stereospecific: they recognise and cleave L-amino acid sequences and largely ignore D-amino acid sequences.

Cyclisation is another strategy. Constraining a peptide into a ring structure, either through a disulfide bridge, a lactam bond, or other cyclisation chemistries, reduces conformational flexibility and often dramatically slows degradation. It also tends to improve selectivity because the rigid structure is a tighter fit for the target receptor.

PEGylation, attachment of polyethylene glycol chains, increases hydrodynamic radius, slows renal clearance, and can sterically block proteases from accessing cleavage sites. The GLP-1 receptor agonist class of molecules is a well-studied example of how structural modifications (including fatty acid conjugation to enable albumin binding) can extend in vivo half-life from minutes to days or longer, which is what made weekly dosing formulations possible.

Understanding these pharmacokinetics; how the body handles a molecule over time, is central to interpreting any peptide research. A finding in a cell assay or animal model that uses a native, unmodified peptide sequence may not translate directly to an in vivo human context precisely because the degradation profile changes everything.

The Australian regulatory context

This is worth being direct about. Many peptides that circulate in fitness and wellness spaces online are not approved by the Therapeutic Goods Administration (TGA) and do not appear on the Australian Register of Therapeutic Goods (the ARTG). The TGA has made its position on this clear through compliance campaigns targeting the supply of unapproved peptides, supplying them without approval is illegal in Australia, full stop.

Some peptide-based medicines do have a lawful pathway: a prescriber may access them for a specific patient via the TGA's Special Access Scheme, or through the Authorised Prescriber framework, depending on the substance and schedule. Prescription-only medicines under Schedule 4 require a valid prescription. The stability and degradation science I've described here is the underlying chemistry relevant to understanding how these molecules behave; not a guide to seeking them out.

I'd also note that from a pure pharmacology standpoint, the stability question makes the provenance and storage history of any peptide-based product genuinely consequential. Good Manufacturing Practice (GMP) standards exist partly because the chain of custody, from synthesis to patient, is where peptide degradation risk accumulates. A molecule that hasn't been stored correctly may look identical to an intact one on a label but behave very differently in a biological system. That's not a minor caveat.

I was listening to a true-crime podcast on a long run last Sunday; the kind where the forensic chemist is explaining how a sample degraded in evidence storage and changed the whole analytical picture. And I genuinely thought: yes, that is exactly what happens with peptides too. Molecules don't respect sloppy handling, whatever context they're in.

Sources

, Priya Nandakumar, Pharmacology writer, peptides & PK

Common questions

Why do peptides degrade so quickly in the body?: The body contains a large number of proteases and peptidases — enzymes specifically designed to cleave peptide bonds. These are found in plasma, the gastrointestinal tract, and tissue membranes. Most endogenous peptides are designed to act rapidly and then clear quickly, so the biological machinery for breaking them down is efficient and widespread. Unmodified, native peptide sequences are often degraded within minutes of entering biological fluids.
What is the difference between enzymatic and chemical peptide degradation?: Enzymatic degradation involves proteases recognising and cleaving specific sequences in a peptide chain — it's biologically driven and the dominant pathway in vivo. Chemical degradation, by contrast, occurs independently of enzymes; it includes hydrolysis driven by pH and temperature, and oxidation of vulnerable amino acid side chains (such as methionine or cysteine) triggered by oxygen, light, or metal ions. Both pathways reduce a peptide's biological activity, but they operate through different mechanisms and are managed differently in formulation and storage.
How does lyophilisation (freeze-drying) help preserve peptides?: Lyophilisation removes water from a peptide sample, which dramatically slows the hydrolysis reactions responsible for peptide bond cleavage and the oxidative reactions that degrade sensitive residues. In the dry, lyophilised state, stored at appropriate temperature, peptides are generally far more stable than in aqueous solution. Once a peptide is reconstituted in a liquid vehicle, the stability window shortens considerably — which is why reconstituted solutions are typically used promptly or stored under refrigeration.
What structural modifications can improve peptide stability?: Researchers have developed several strategies: substituting D-amino acids (mirror-image forms) at susceptible sites blocks recognition by stereospecific proteases; N-methylation of backbone amide nitrogens disrupts protease binding; cyclisation through disulfide bridges or lactam bonds constrains the molecule and reduces enzymatic access; and PEGylation — attaching polyethylene glycol chains — can sterically shield cleavage sites while also reducing renal clearance. Each modification changes the pharmacokinetic profile, often substantially.
Are peptides legally available in Australia?: Some peptide-based medicines are legally available in Australia when prescribed under the appropriate regulatory framework — either as registered therapeutic goods on the ARTG, or accessed by a prescriber through the TGA's Special Access Scheme or the Authorised Prescriber pathway. However, many peptides marketed online, particularly for performance or anti-ageing purposes, are not TGA-approved. Supplying unapproved therapeutic goods in Australia is illegal under the Therapeutic Goods Act 1989, and the TGA has actively enforced compliance in this area.